Bayer AG stock continues to experience significant and unpredictable fluctuations mainly due to their exposure to various ongoing litigation cases, particularly the Roundup lawsuits. Despite the volatility, multiple positive factors are shining through, including strong
pharma results and
growth factors forecasted by the company for FY26. Though it experienced a Q4 loss and a cautious FY25 outlook, it still managed to secure an EU nod for the six-month Eylea treatment. However, a larger than expected drop in adjusted profit has resulted in significant stock market scrutiny. Bayer's stock seems to oscillate from plunging due to cash-raising plans and a
20-year low forecast for 2025 earnings, to rising after beating expectations and recording strong demand for certain pharmaceuticals. The current stock performance is seen as a
contrarian investment, recommending caution while also presenting potential gains. There is increasing pressure on Bayer's CEO and management to mitigate issues contributing to the company's volatility. Additionally, the stock is now seen as being potentially undervalued, making it an investment worth consideration.
BAYER Stocks News Analytics from Fri, 16 Aug 2024 07:00:00 GMT to Fri, 23 May 2025 11:30:15 GMT -
Rating 3
- Innovation -2
- Information 8
- Rumor -1
